AP2015008915A0 - Combination of a imidazopyridazine derivative and a mitotic agent for the treatment of cancer - Google Patents

Combination of a imidazopyridazine derivative and a mitotic agent for the treatment of cancer

Info

Publication number
AP2015008915A0
AP2015008915A0 AP2015008915A AP2015008915A AP2015008915A0 AP 2015008915 A0 AP2015008915 A0 AP 2015008915A0 AP 2015008915 A AP2015008915 A AP 2015008915A AP 2015008915 A AP2015008915 A AP 2015008915A AP 2015008915 A0 AP2015008915 A0 AP 2015008915A0
Authority
AP
ARIPO
Prior art keywords
cancer
treatment
combination
mitotic agent
imidazopyridazine derivative
Prior art date
Application number
AP2015008915A
Other languages
English (en)
Inventor
Gerhard Siemeister
Antje Margret Wengner
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48578942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2015008915(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of AP2015008915A0 publication Critical patent/AP2015008915A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2015008915A 2013-06-13 2014-06-11 Combination of a imidazopyridazine derivative and a mitotic agent for the treatment of cancer AP2015008915A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13171818 2013-06-13
PCT/EP2014/062133 WO2014198776A1 (fr) 2013-06-13 2014-06-11 Combinaison d'un dérivé d'imidazopyridazine et d'un agent mitotique pour le traitement du cancer

Publications (1)

Publication Number Publication Date
AP2015008915A0 true AP2015008915A0 (en) 2015-12-31

Family

ID=48578942

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2015008915A AP2015008915A0 (en) 2013-06-13 2014-06-11 Combination of a imidazopyridazine derivative and a mitotic agent for the treatment of cancer

Country Status (17)

Country Link
US (1) US20160175306A1 (fr)
EP (1) EP3007698A1 (fr)
JP (1) JP2016521740A (fr)
KR (1) KR20160018749A (fr)
CN (1) CN105392484A (fr)
AP (1) AP2015008915A0 (fr)
AU (1) AU2014280224A1 (fr)
CA (1) CA2914995A1 (fr)
CL (1) CL2015003606A1 (fr)
EA (1) EA028800B1 (fr)
HK (1) HK1222341A1 (fr)
MA (1) MA38657A1 (fr)
MX (1) MX2015017245A (fr)
PH (1) PH12015502756A1 (fr)
SG (1) SG11201510034QA (fr)
TN (1) TN2015000544A1 (fr)
WO (1) WO2014198776A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201613927A (en) * 2014-09-01 2016-04-16 Bayer Pharma AG Method for preparation of substituted imidazopyridazines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541243B (zh) * 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
CN104284896B (zh) * 2012-03-14 2016-06-01 拜耳知识产权有限责任公司 取代的咪唑并哒嗪
WO2014020041A1 (fr) * 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinaisons pour le traitement du cancer
TW201437211A (zh) * 2013-03-01 2014-10-01 Bayer Pharma AG 經取代咪唑并嗒□

Also Published As

Publication number Publication date
EA028800B1 (ru) 2017-12-29
AU2014280224A1 (en) 2016-01-07
CN105392484A (zh) 2016-03-09
CL2015003606A1 (es) 2016-08-12
EA201600014A1 (ru) 2016-06-30
CA2914995A1 (fr) 2014-12-18
JP2016521740A (ja) 2016-07-25
US20160175306A1 (en) 2016-06-23
WO2014198776A1 (fr) 2014-12-18
SG11201510034QA (en) 2016-01-28
TN2015000544A1 (en) 2017-04-06
KR20160018749A (ko) 2016-02-17
MA38657A1 (fr) 2018-05-31
EP3007698A1 (fr) 2016-04-20
HK1222341A1 (zh) 2017-06-30
MX2015017245A (es) 2016-07-20
PH12015502756A1 (en) 2016-03-14

Similar Documents

Publication Publication Date Title
IL268094B (en) History of heterocyclic compounds for use in the treatment of lung cancer
IL245731A0 (en) Combined treatment for cancer
HUE057061T2 (hu) Kombinációs terápia rák kezelésére
HK1251494A1 (zh) 治療癌症的方法和組合物
SG10201912275YA (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3kd related disorders
EP2968343A4 (fr) Polythérapie pour traiter un cancer
GB201322725D0 (en) Cancer therapy
IL244353A0 (en) Compounds and use for cancer treatment
HK1220900A1 (zh) 癌症的治療
PT3089749T (pt) Preparações combinadas para o tratamento de cancro
SG11201507847UA (en) Cancer therapy
HK1222548A1 (zh) 治療惡性腫瘤的藥物組合
HK1219879A1 (zh) 用於治療癌症的包含 激酶抑制劑和有絲分裂抑制劑的組合
EP3003489A4 (fr) Agents cytotoxiques destinés au traitement du cancer
HK1223547A1 (zh) 癌症治療方法
EP2961412A4 (fr) Cancérothérapie
HK1222341A1 (zh) 咪唑並噠嗪衍生物與有絲分裂試劑的聯用藥用於治療癌症
PL3016948T3 (pl) 2-acyloaminotiazole do leczenia nowotworów
HK1214502A1 (zh) 用於癌症治療的 和卡培他濱的組合
GB201322346D0 (en) Combination treatment of cancer
GB201317564D0 (en) Therapeutic for the treatment of Lung Cancer
GB201317213D0 (en) Cancer Therapy
GB201300546D0 (en) Cancer Treatment